Drugs / mouse gp100 plasmid DNA vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00398073 | Oct 2006 → Mar 2011 | cutaneous melanoma, ocular melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00104845 | Sep 2004 → Sep 2011 | cutaneous melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mouse gp100 plasmid DNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00104845 ↗ |
| Modality | Vaccine | “mouse gp100 DNA vaccine” NCT00104845 ↗ |
| Route | Intramuscular | “Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16” NCT00104845 ↗ |